# Safety of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery

> **NCT07036510** · PHASE1 · RECRUITING · sponsor: **EyeD Pharma** · enrollment: 18 (estimated)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** TimoD implant
- **DEVICE:** Injector system

## Key facts

- **NCT ID:** NCT07036510
- **Lead sponsor:** EyeD Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-12
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07036510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07036510, "Safety of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT07036510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*